Galafold

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX I 
  

SUMMARY OF PRODUCT CHARACTERISTICS 
 
 
 
 
 
  



2 

This medicinal product is subject to additional monitoring. This will allow quick identification of 
new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 
See section 4.8 for how to report adverse reactions. 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Galafold 123 mg hard capsules  
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat.  
For the full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Hard capsule.  
Size 2 hard capsule (6.4x18.0 mm) with an opaque blue cap and opaque white body with “A1001” 
printed in black, containing white to pale brown powder.  
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a 
confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable 
mutation (see the tables in section 5.1).  
 
4.2 Posology and method of administration 
 
Treatment with Galafold should be initiated and supervised by specialist physicians experienced in the 
diagnosis and treatment of Fabry disease. Galafold is not intended for concomitant use with enzyme 
replacement therapy (see section 4.4). 
 
Posology 
 
The recommended dosage regimen in adults and adolescents 16 years and older is 123 mg migalastat 
(1 capsule) once every other day at the same time of day. 
 
Missed dose  
Galafold should not be taken on 2 consecutive days. If a dose is missed entirely for the day, the patient 
should take the missed dose of Galafold only if it is within 12 hours of the normal time the dose is 
taken. If more than 12 hours has passed the patient should resume taking Galafold at the next planned 
dosing day and time according to the every other day dosing schedule. 
 
Paediatric population 
The safety and efficacy of Galafold in children aged 0 to 15 years has not yet been established. No 
data are available. 
 
Special populations 
 
Elderly population 
No dosage adjustment is required based on age (see section 5.2). 



3 

 
Renal impairment 
Galafold is not recommended for use in patients with Fabry disease who have estimated GFR less than 
30 mL/min/1.73 m2 (see section 5.2). 
 
Hepatic impairment 
No dosage adjustment of Galafold is required in patients with hepatic impairment (see section 5.2). 
 
Method of administration  
 
For oral use. Galafold exposure is decreased by approximately 40% when taken with food and 
therefore food should not be consumed at least 2 hours before and 2 hours after taking Galafold to give 
a minimum 4 hours fast. Clear liquids, including carbonated drinks, can be consumed during this 
period. Galafold should be taken every other day at the same time of day to ensure optimal benefits to 
the patient.  
 
Capsules must be swallowed whole. The capsules must not be cut, crushed, or chewed.  
 
4.3 Contraindications 
 
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
 
4.4 Special warnings and precautions for use 
 
It is advised to periodically monitor renal function, echocardiographic parameters and biochemical 
markers (every 6 months) in patients initiated on or switched to Galafold. In case of meaningful 
clinical deterioration, further clinical evaluation or discontinuation of treatment with Galafold should 
be considered. 
 
Galafold is not indicated for use in patients with non-amenable mutations (see section 5.1).  
 
No reduction in proteinuria was observed in patients treated with Galafold.  
 
Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated 
GFR less than 30 mL/min/1.73m2 (see section 5.2). 
 
Limited data suggest that co-administration of a single dose of Galafold and a standard enzyme 
replacement therapy infusion results in an increased exposure to agalsidase of up to 5-fold. This study 
also indicated that agalsidase has no effect on the pharmacokinetics of migalastat. Galafold is not 
intended for concomitant use with enzyme replacement therapy. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
Based upon in vitro data, migalastat is not an inducer of CYP1A2, 2B6, or 3A4. Furthermore, 
migalastat is not an inhibitor or a substrate of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 
3A4/5. Migalastat is not a substrate for MDR1 or BCRP, nor is it an inhibitor of BCRP, MDR1, or 
BSEP human efflux transporters. In addition, migalastat is not a substrate for MATE1, MATE2-K, 
OAT1, OAT3, or OCT2, nor is it an inhibitor of OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, 
MATE1, or MATE2-K human uptake transporters. 
 
4.6 Fertility, pregnancy and lactation 
 
Women of childbearing potential/Contraception in males and females 
Galafold is not recommended in women of childbearing potential not using contraception.  
 



4 

Pregnancy 
There are limited data from the use of Galafold in pregnant women. In rabbits, developmental toxicity 
was observed only at maternally toxic doses (see section 5.3). Galafold is not recommended during 
pregnancy. 
 
Breast-feeding 
It is not known whether Galafold is secreted in human milk. However, migalastat has been shown to 
be expressed in the milk of lactating rats. Accordingly, a risk of migalastat exposure to the 
breast-feeding infant cannot be excluded. A decision must be made whether to discontinue 
breast-feeding or to discontinue Galafold, taking into account the benefit of breast-feeding for the 
child relative to the benefit of therapy for the mother. 
 
Fertility 
The effects of Galafold on fertility in humans have not been studied. Transient and fully reversible 
infertility in male rats was associated with migalastat treatment at all doses assessed. Complete 
reversibility was seen after 4 weeks off-dose. Similar findings have been noted pre-clinically 
following treatment with other iminosugars (see section 5.3). Migalastat did not affect fertility in 
female rats.  
 
4.7 Effects on ability to drive and use machines 
 
Galafold has no or negligible influence on the ability to drive and use machines. 
 
4.8 Undesirable effects 
 
Summary of the safety profile 
The most common adverse reaction was headache, which was experienced by approximately 10% of 
patients who received Galafold.  
 
Tabulated list of adverse reactions  
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 
to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated 
from the available data). Within each frequency grouping, adverse reactions are presented in order of 
decreasing frequency within each System Organ Class.  
 

Table 1: Adverse reactions with Galafold in clinical trials 

System Organ Class Very common  Common 

Psychiatric disorders  Depression 

Nervous system disorders Headache Paraesthesia Dizziness 
Hypoaesthesia 

Ear and labyrinth disorders  Vertigo 

Cardiac disorders  Palpitations 

Respiratory, thoracic, and 
mediastinal disorders 

 Dyspnoea Epistaxis 



5 

System Organ Class Very common  Common 

Gastrointestinal disorders  Diarrhoea Nausea 
Abdominal pain 
Constipation 
Dry mouth 
Defaecation urgency 
Dyspepsia 

Skin and subcutaneous tissue 
disorders 

 Rash Pruritus 

Musculoskeletal and 
connective tissue disorders 

 Muscle spasms Myalgia 
Torticollis 
Pain in extremity 

Renal and urinary disorders  Proteinuria 

General disorders and 
administration site conditions 

 Fatigue 
Pain 

Investigations  Blood creatine phosphokinase 
increased 
Weight increased 

 
Reporting of suspected adverse reactions 
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V. 
 
4.9 Overdose 
 
In case of overdose, general medical care is recommended. Headache and dizziness were the most 
common adverse reactions reported at doses of Galafold of up to 1250 mg and 2000 mg, respectively. 
 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1  Pharmacodynamic properties 
 
Pharmacotherapeutic group: Various alimentary tract and metabolism products ATC code: A16AX14 
 
Fabry disease is a progressive X-linked lysosomal storage disorder which affects males and females. 
Fabry disease-causing mutations in the GLA gene result in a deficiency of the lysosomal enzyme 
α-galactosidase A (α-Gal A) that is required for glycosphingolipid substrate (e.g., GL-3, lyso-Gb3) 
metabolism. Reduced α-Gal A activity is, therefore, associated with the progressive accumulation of 
substrate in vulnerable organs and tissues, which leads to the morbidity and mortality associated with 
Fabry disease. 
 
Mechanism of action  
 
Certain GLA mutations can result in the production of abnormally folded and unstable mutant forms of 
α-Gal A. Migalastat is a pharmacological chaperone that is designed to selectively and reversibly bind 
with high affinity to the active sites of certain mutant forms of α-Gal A, the genotypes of which are 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


6 

referred to as amenable mutations. Migalastat binding stabilizes these mutant forms of α-Gal A in the 
endoplasmic reticulum and facilitates their proper trafficking to lysosomes. Once in lysosomes 
dissociation of migalastat restores α-Gal A activity, leading to the catabolism of GL-3 and related 
substrates. 
 
The GLA mutations amenable to treatment with Galafold are listed in Table 2 below. The GLA 
mutations are also accessible by health care providers at www.galafoldamenabilitytable.com. 
 
The nucleotide changes listed represent potential DNA sequence changes that result in the amino acid 
mutation. The amino acid mutation (protein sequence change) is most relevant when determining 
amenability. If a double mutation is present on the same chromosome (males and females), that patient 
is amenable if the double mutation is present in one entry in Table 2 (e.g., D55V/Q57L). If a double 
mutation is present on different chromosomes (only in females) that patient is amenable if either one 
of the individual mutations is present in Table 2. 
 
Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.7C>G c.C7G L3V 
c.8T>C c.T8C L3P 
c.[11G>T; 620A>C] c.G11T/A620C R4M/Y207S 
c.13A>G c.A13G N5D 
c.15C>G c.C15G N5K 
c.16C>A c.C16A P6T 
c.16C>T c.C16T P6S 
c.17C>A c.C17A P6Q 
c.17C>G c.C17G P6R 
c.17C>T c.C17T P6L 
c.19G>A c.G19A E7K 
c.20A>T c.A20T E7V 
c.21A>T c.A21T E7D 
c.22C>A c.C22A L8I 
c.23T>A c.T23A L8Q 
c.23T>C c.T23C L8P 
c.25C>T c.C25T H9Y 
c.26A>G c.A26G H9R 
c.26A>T c.A26T H9L 
c.27T>A c.T27A H9Q 
c.28C>A c.C28A L10M 
c.28C>G c.C28G L10V 
c.29T>A c.T29A L10Q 
c.29T>C c.T29C L10P 
c.29T>G c.T29G L10R 
c.31G>A c.G31A G11S 
c.31G>C c.G31C G11R 
c.31G>T c.G31T G11C 
c.32G>A c.G32A G11D 
c.32G>T c.G32T G11V 
c.34T>A c.T34A C12S 
c.34T>C c.T34C C12R 
c.34T>G c.T34G C12G 
c.35G>A c.G35A C12Y 
c.37G>A c.G37A A13T 

http://listed/
http://www.galafoldamenabilitytable.com/


7 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.37G>C c.G37C A13P 
c.38C>A c.C38A A13E 
c.38C>G c.C38G A13G 
c.40C>G c.C40G L14V 
c.40C>T c.C40T L14F 
c.41T>A c.T41A L14H 
c.43G>A c.G43A A15T 
c.44C>G c.C44G A15G 
c.49C>A c.C49A R17S 
c.49C>G c.C49G R17G 
c.49C>T c.C49T R17C 
c.50G>A c.G50A R17H 
c.50G>C c.G50C R17P 
c.52T>A c.T52A F18I 
c.53T>G c.T53G F18C 
c.54C>G c.C54G F18L 
c.58G>C c.G58C A20P 
c.59C>A c.C59A A20D 
c.59C>G c.C59G A20G 
c.62T>A c.T62A L21H 
c.64G>A c.G64A V22I 
c.64G>C c.G64C V22L 
c.64G>T c.G64T V22F 
c.65T>C c.T65C V22A 
c.65T>G c.T65G V22G 
c.67T>A c.T67A S23T 
c.67T>C c.T67C S23P 
c.70T>C or c.70T>A c.T70C or c.T70A W24R 
c.70T>G c.T70G W24G 
c.71G>C c.G71C W24S 
c.72G>C or c.72G>T c.G72C or c.G72T W24C 
c.73G>C c.G73C D25H 
c.77T>A c.T77A I26N 
c.79C>A c.C79A P27T 
c.79C>G c.C79G P27A 
c.79C>T c.C79T P27S 
c.80C>T c.C80T P27L 
c.82G>C c.G82C G28R 
c.82G>T c.G82T G28W 
c.83G>A c.G83A G28E 
c.85G>C c.G85C A29P 
c.86C>A c.C86A A29D 
c.86C>G c.C86G A29G 
c.86C>T c.C86T A29V 
c.88A>G c.A88G R30G 
c.94C>A c.C94A L32M 
c.94C>G c.C94G L32V 
c.95T>A c.T95A L32Q 
c.95T>C c.T95C L32P 
c.95T>G c.T95G L32R 



8 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.97G>C c.G97C D33H 
c.97G>T c.G97T D33Y 
c.98A>C c.A98C D33A 
c.98A>G c.A98G D33G 
c.98A>T c.A98T D33V 
c.99C>G c.C99G D33E 
c.100A>C c.A100C N34H 
c.100A>G c.A100G N34D 
c.101A>C c.A101C N34T 
c.101A>G c.A101G N34S 
c.102T>G or c.102T>A c.T102G or c.T102A N34K 
c.103G>C or c.103G>A c.G103C or c.G103A G35R 
c.104G>A c.G104A G35E 
c.104G>C c.G104C G35A 
c.104G>T c.G104T G35V 
c.106T>A c.T106A L36M 
c.106T>G c.T106G L36V 
c.107T>C c.T107C L36S 
c.107T>G c.T107G L36W 
c.108G>C or c.108G>T c.G108C or c.G108T L36F 
c.109G>A c.G109A A37T 
c.109G>T c.G109T A37S 
c.110C>A c.C110A A37E 
c.110C>G c.C110G A37G 
c.110C>T c.C110T A37V 
c.112A>G c.A112G R38G 
c.112A>T c.A112T R38W 
c.113G>T c.G113T R38M 
c.114G>C c.G114C R38S 
c.115A>G c.A115G T39A 
c.115A>T c.A115T T39S 
c.116C>A c.C116A T39K 
c.116C>G c.C116G T39R 
c.116C>T c.C116T T39M 
c.121A>G c.A121G T41A 
c.122C>A c.C122A T41N 
c.122C>G c.C122G T41S 
c.122C>T c.C122T T41I 
c.124A>C or c.124A>T c.A124C or c.A124T M42L 
c.124A>G c.A124G M42V 
c.125T>A c.T125A M42K 
c.125T>C c.T125C M42T 
c.125T>G c.T125G M42R 
c.126G>A or c.126G>C or 
c.126G>T 

c.G126A or c.G126C or c.G126T M42I 

c.128G>C c.G128C G43A 
c.133C>A c.C133A L45M 
c.133C>G c.C133G L45V 
c.136C>A c.C136A H46N 
c.136C>G c.C136G H46D 



9 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.137A>C c.A137C H46P 
c.138C>G c.C138G H46Q 
c.142G>C c.G142C E48Q 
c.143A>C c.A143C E48A 
c.149T>A c.T149A F50Y 
c.151A>G c.A151G M51V 
c.152T>A c.T152A M51K 
c.152T>C c.T152C M51T 
c.152T>G c.T152G M51R 
c.153G>A or c.153G>T or 
c.153G>C 

c.G153A or c.G153T or c.G153C M51I 

c.157A>C c.A157C N53H 
c.[157A>C; 158A>T] c.A157C/A158T N53L 
c.157A>G c.A157G N53D 
c.157A>T c.A157T N53Y 
c.158A>C c.A158C N53T 
c.158A>G c.A158G N53S 
c.158A>T c.A158T N53I 
c.159C>G or c.159C>A c.C159G or c.C159A N53K 
c.160C>G c.C160G L54V 
c.160C>T c.C160T L54F 
c.161T>A c.T161A L54H 
c.161T>C c.T161C L54P 
c.161T>G c.T161G L54R 
c.163G>C c.G163C D55H 
c.163G>T c.G163T D55Y 
c.164A>C c.A164C D55A 
c.164A>G c.A164G D55G 
c.164A>T c.A164T D55V 
c.[164A>T; 170A>T] c.A164T/A170T D55V/Q57L 
c.165C>G c.C165G D55E 
c.167G>A c.G167A C56Y 
c.167G>T c.G167T C56F 
c.168C>G c.C168G C56W 
c.170A>G c.A170G Q57R 
c.170A>T c.A170T Q57L 
c.172G>A c.G172A E58K 
c.175G>A c.G175A E59K 
c.175G>C c.G175C E59Q 
c.176A>C c.A176C E59A 
c.176A>G c.A176G E59G 
c.176A>T c.A176T E59V 
c.177G>C c.G177C E59D 
c.178C>A c.C178A P60T 
c.178C>G c.C178G P60A 
c.178C>T c.C178T P60S 
c.179C>A c.C179A P60Q 
c.179C>G c.C179G P60R 
c.179C>T c.C179T P60L 
c.182A>T c.A182T D61V 



10 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.183T>A c.T183A D61E 
c.184_185insTAG c.184_185insTAG S62delinsLA 
c.184T>C c.T184C S62P 
c.184T>G c.T184G S62A 
c.185C>A c.C185A S62Y 
c.185C>G c.C185G S62C 
c.185C>T c.C185T S62F 
c.190A>C c.A190C I64L 
c.190A>G c.A190G I64V 
c.193A>G c.A193G S65G 
c.193A>T c.A193T S65C 
c.195T>A c.T195A S65R 
c.196G>A c.G196A E66K 
c.197A>G c.A197G E66G 
c.197A>T c.A197T E66V 
c.198G>C c.G198C E66D 
c.199A>C c.A199C K67Q 
c.199A>G c.A199G K67E 
c.200A>C c.A200C K67T 
c.200A>T c.A200T K67M 
c.201G>C c.G201C K67N 
c.202C>A c.C202A L68I 
c.205T>A c.T205A F69I 
c.206T>A c.T206A F69Y 
c.207C>A or c.207C>G c.C207A or c.C207G F69L 
c.208A>T c.A208T M70L 
c.209T>A c.T209A M70K 
c.209T>G c.T209G M70R 
c.210G>C c.G210C M70I 
c.211G>C c.G211C E71Q 
c.212A>C c.A212C E71A 
c.212A>G c.A212G E71G 
c.212A>T c.A212T E71V 
c.213G>C c.G213C E71D 
c.214A>G c.A214G M72V 
c.214A>T c.A214T M72L 
c.215T>C c.T215C M72T 
c.216G>A or c.216G>T or 
c.216G>C 

c.G216A or c.G216T or c.G216C M72I 

c.217G>A c.G217A A73T 
c.217G>T c.G217T A73S 
c.218C>T c.C218T A73V 
c.220G>A c.G220A E74K 
c.221A>G c.A221G E74G 
c.221A>T c.A221T E74V 
c.222G>C c.G222C E74D 
c.223C>T c.C223T L75F 
c.224T>C c.T224C L75P 
c.226A>G c.A226G M76V 
c.227T>C c.T227C M76T 



11 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.229G>A c.G229A V77I 
c.229G>C c.G229C V77L 
c.232T>C c.T232C S78P 
c.233C>T c.C233T S78L 
c.235G>A c.G235A E79K 
c.235G>C c.G235C E79Q 
c.236A>C c.A236C E79A 
c.236A>G c.A236G E79G 
c.236A>T c.A236T E79V 
c.237A>T c.A237T E79D 
c.238G>A c.G238A G80S 
c.238G>T c.G238T G80C 
c.239G>A c.G239A G80D 
c.239G>C c.G239C G80A 
c.239G>T c.G239T G80V 
c.242G>T c.G242T W81L 
c.244A>G c.A244G K82E 
c.245A>C c.A245C K82T 
c.245A>G c.A245G K82R 
c.245A>T c.A245T K82M 
c.246G>C c.G246C K82N 
c.247G>A c.G247A D83N 
c.248A>C c.A248C D83A 
c.248A>G c.A248G D83G 
c.248A>T c.A248T D83V 
c.249T>A c.T249A D83E 
c.250G>A c.G250A A84T 
c.250G>C c.G250C A84P 
c.250G>T c.G250T A84S 
c.251C>A c.C251A A84E 
c.251C>G c.C251G A84G 
c.251C>T c.C251T A84V 
c.253G>A c.G253A G85S 
c.[253G>A; 254G>A] c.G253A/G254A G85N 
c.[253G>A; 254G>T; 255T>G] c.G253A/G254T/T255G G85M 
c.253G>C c.G253C G85R 
c.253G>T c.G253T G85C 
c.254G>A c.G254A G85D 
c.254G>C c.G254C G85A 
c.257A>T c.A257T Y86F 
c.260A>G c.A260G E87G 
c.261G>C or c.261G>T c.G261C or c.G261T E87D 
c.262T>A c.T262A Y88N 
c.262T>C c.T262C Y88H 
c.263A>C c.A263C Y88S 
c.263A>G c.A263G Y88C 
c.265C>G c.C265G L89V 
c.265C>T c.C265T L89F 
c.271A>C c.A271C I91L 
c.271A>T c.A271T I91F 



12 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.272T>C c.T272C I91T 
c.272T>G c.T272G I91S 
c.273T>G c.T273G I91M 
c.286A>G c.A286G M96V 
c.286A>T c.A286T M96L 
c.287T>C c.T287C M96T 
c.288G>A or c.288G>T or 
c.288G>C 

c.G288A or c.G288T or c.G288C M96I 

c.289G>A c.G289A A97T 
c.289G>C c.G289C A97P 
c.289G>T c.G289T A97S 
c.290C>A c.C290A A97D 
c.290C>T c.C290T A97V 
c.293C>A c.C293A P98H 
c.293C>G c.C293G P98R 
c.293C>T c.C293T P98L 
c.295C>G c.C295G Q99E 
c.296A>C c.A296C Q99P 
c.296A>G c.A296G Q99R 
c.296A>T c.A296T Q99L 
c.301G>C c.G301C D101H 
c.302A>C c.A302C D101A 
c.302A>G c.A302G D101G 
c.302A>T c.A302T D101V 
c.303T>A c.T303A D101E 
c.304T>A c.T304A S102T 
c.304T>C c.T304C S102P 
c.304T>G c.T304G S102A 
c.305C>T c.C305T S102L 
c.310G>A c.G310A G104S 
c.311G>A c.G311A G104D 
c.311G>C c.G311C G104A 
c.311G>T c.G311T G104V 
c.313A>G c.A313G R105G 
c.314G>A c.G314A R105K 
c.314G>C c.G314C R105T 
c.314G>T c.G314T R105I 
c.316C>A c.C316A L106I 
c.316C>G c.C316G L106V 
c.316C>T c.C316T L106F 
c.317T>A c.T317A L106H 
c.317T>C c.T317C L106P 
c.319C>A c.C319A Q107K 
c.319C>G c.C319G Q107E 
c.320A>G c.A320G Q107R 
c.321G>C c.G321C Q107H 
c.322G>A c.G322A A108T 
c.323C>A c.C323A A108E 
c.323C>T c.C323T A108V 
c.325G>A c.G325A D109N 



13 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.325G>C c.G325C D109H 
c.325G>T c.G325T D109Y 
c.326A>C c.A326C D109A 
c.326A>G c.A326G D109G 
c.327C>G c.C327G D109E 
c.328C>A c.C328A P110T 
c.334C>G c.C334G R112G 
c.335G>A c.G335A R112H 
c.335G>T c.G335T R112L 
c.337T>A c.T337A F113I 
c.337T>C or c.339T>A or 
c.339T>G 

c.T337C or c.T339A or c.T339G F113L 

c.337T>G c.T337G F113V 
c.338T>A c.T338A F113Y 
c.341C>T c.C341T P114L 
c.343C>A c.C343A H115N 
c.343C>G c.C343G H115D 
c.346G>C c.G346C G116R 
c.350T>C c.T350C I117T 
c.351T>G c.T351G I117M 
c.352C>T c.C352T R118C 
c.361G>A c.G361A A121T 
c.362C>T c.C362T A121V 
c.367T>A c.T367A Y123N 
c.367T>G c.T367G Y123D 
c.368A>C c.A368C Y123S 
c.368A>G c.A368G Y123C 
c.368A>T c.A368T Y123F 
c.370G>A c.G370A V124I 
c.371T>G c.T371G V124G 
c.373C>A c.C373A H125N 
c.373C>G c.C373G H125D 
c.373C>T c.C373T H125Y 
c.374A>G c.A374G H125R 
c.374A>T c.A374T H125L 
c.376A>G c.A376G S126G 
c.376A>T c.A376T S126C 
c.377G>T c.G377T S126I 
c.379A>G c.A379G K127E 
c.383G>A c.G383A G128E 
c.383G>C c.G383C G128A 
c.385C>G c.C385G L129V 
c.388A>C c.A388C K130Q 
c.389A>T c.A389T K130M 
c.390G>C c.G390C K130N 
c.391C>G c.C391G L131V 
c.397A>C c.A397C I133L 
c.397A>G c.A397G I133V 
c.397A>T c.A397T I133F 
c.398T>C c.T398C I133T 



14 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.399T>G c.T399G I133M 
c.[399T>G; 434T>C] c.T399G/T434C I133M/F145S 
c.403G>A c.G403A A135T 
c.403G>T c.G403T A135S 
c.404C>A c.C404A A135E 
c.404C>G c.C404G A135G 
c.404C>T c.C404T A135V 
c.406G>A c.G406A D136N 
c.407A>C c.A407C D136A 
c.407A>T c.A407T D136V 
c.408T>A or c.408T>G c.T408A or c.T408G D136E 
c.409G>A c.G409A V137I 
c.409G>C c.G409C V137L 
c.410T>A c.T410A V137D 
c.410T>C c.T410C V137A 
c.410T>G c.T410G V137G 
c.413G>C c.G413C G138A 
c.415A>C c.A415C N139H 
c.415A>T c.A415T N139Y 
c.416A>G c.A416G N139S 
c.416A>T c.A416T N139I 
c.417T>A c.T417A N139K 
c.418A>C c.A418C K140Q 
c.418A>G c.A418G K140E 
c.419A>C c.A419C K140T 
c.419A>G c.A419G K140R 
c.419A>T c.A419T K140I 
c.420A>T c.A420T K140N 
c.421A>T c.A421T T141S 
c.427G>A c.G427A A143T 
c.428C>A c.C428A A143E 
c.428C>G c.C428G A143G 
c.428C>T c.C428T A143V 
c.430G>A c.G430A G144S 
c.430G>C c.G430C G144R 
c.430G>T c.G430T G144C 
c.431G>A c.G431A G144D 
c.431G>C c.G431C G144A 
c.431G>T c.G431T G144V 
c.433T>G c.T433G F145V 
c.434T>A c.T434A F145Y 
c.434T>C c.T434C F145S 
c.434T>G c.T434G F145C 
c.435C>G c.C435G F145L 
c.436C>A c.C436A P146T 
c.436C>G c.C436G P146A 
c.436C>T c.C436T P146S 
c.437C>A c.C437A P146H 
c.437C>G c.C437G P146R 
c.437C>T c.C437T P146L 



15 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.440G>C c.G440C G147A 
c.442A>G c.A442G S148G 
c.442A>T c.A442T S148C 
c.443G>C c.G443C S148T 
c.446T>G c.T446G F149C 
c.449G>A c.G449A G150E 
c.449G>T c.G449T G150V 
c.451T>G c.T451G Y151D 
c.452A>C c.A452C Y151S 
c.452A>G c.A452G Y151C 
c.454T>A c.T454A Y152N 
c.454T>C c.T454C Y152H 
c.454T>G c.T454G Y152D 
c.455A>C c.A455C Y152S 
c.455A>G c.A455G Y152C 
c.455A>T c.A455T Y152F 
c.457G>A c.G457A D153N 
c.457G>C c.G457C D153H 
c.457G>T c.G457T D153Y 
c.458A>C c.A458C D153A 
c.458A>T c.A458T D153V 
c.465T>A or c.465T>G c.T465A or c.T465G D155E 
c.466G>A c.G466A A156T 
c.466G>T c.G466T A156S 
c.467C>G c.C467G A156G 
c.467C>T c.C467T A156V 
c.469C>A c.C469A Q157K 
c.469C>G c.C469G Q157E 
c.470A>C c.A470C Q157P 
c.470A>T c.A470T Q157L 
c.471G>C or c.471G>T c.G471C or c.G471T Q157H 
c.472A>G c.A472G T158A 
c.472A>T c.A472T T158S 
c.473C>A c.C473A T158N 
c.473C>T c.C473T T158I 
c.475T>A c.T475A F159I 
c.475T>G c.T475G F159V 
c.476T>A c.T476A F159Y 
c.476T>G c.T476G F159C 
c.477T>A c.T477A F159L 
c.478G>A c.G478A A160T 
c.478G>T c.G478T A160S 
c.479C>A c.C479A A160D 
c.479C>G c.C479G A160G 
c.479C>T c.C479T A160V 
c.481G>A c.G481A D161N 
c.481G>C c.G481C D161H 
c.481G>T c.G481T D161Y 
c.482A>T c.A482T D161V 
c.484T>G c.T484G W162G 



16 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.485G>C c.G485C W162S 
c.490G>A c.G490A V164I 
c.490G>T c.G490T V164L 
c.491T>C c.T491C V164A 
c.493G>A c.G493A D165N 
c.493G>C c.G493C D165H 
c.494A>C c.A494C D165A 
c.494A>G c.A494G D165G 
c.495T>A c.T495A D165E 
c.496_497delinsTC c.496_497delinsTC L166S 
c.496C>A c.C496A L166M 
c.496C>G c.C496G L166V 
c.[496C>G; 497T>G] c.C496G/T497G L166G 
c.497T>A c.T497A L166Q 
c.499C>A c.C499A L167I 
c.499C>G c.C499G L167V 
c.505T>A c.T505A F169I 
c.505T>G c.T505G F169V 
c.506T>A c.T506A F169Y 
c.506T>C c.T506C F169S 
c.506T>G c.T506G F169C 
c.507T>A c.T507A F169L 
c.511G>A c.G511A G171S 
c.512G>C c.G512C G171A 
c.512G>T c.G512T G171V 
c.517T>C c.T517C Y173H 
c.518A>C c.A518C Y173S 
c.518A>G c.A518G Y173C 
c.518A>T c.A518T Y173F 
c.520T>C c.T520C C174R 
c.520T>G c.T520G C174G 
c.523G>C c.G523C D175H 
c.523G>T c.G523T D175Y 
c.524A>G c.A524G D175G 
c.524A>T c.A524T D175V 
c.525C>G or c.525C>A c.C525G or c.C525A D175E 
c.526A>T c.A526T S176C 
c.528T>A c.T528A S176R 
c.529T>A c.T529A L177M 
c.529T>G c.T529G L177V 
c.530T>C c.T530C L177S 
c.530T>G c.T530G L177W 
c.531G>C c.G531C L177F 
c.532G>A c.G532A E178K 
c.532G>C c.G532C E178Q 
c.533A>C c.A533C E178A 
c.533A>G c.A533G E178G 
c.538T>A c.T538A L180M 
c.538T>G c.T538G L180V 
c.539T>C c.T539C L180S 



17 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.539T>G c.T539G L180W 
c.540G>C or c.540G>T c.G540C or c.G540T L180F 
c.541G>A c.G541A A181T 
c.541G>C c.G541C A181P 
c.542C>T c.C542T A181V 
c.544G>T c.G544T D182Y 
c.545A>C c.A545C D182A 
c.545A>G c.A545G D182G 
c.545A>T c.A545T D182V 
c.546T>A c.T546A D182E 
c.548G>A c.G548A G183D 
c.548G>C c.G548C G183A 
c.550T>A c.T550A Y184N 
c.550T>C c.T550C Y184H 
c.551A>C c.A551C Y184S 
c.551A>G c.A551G Y184C 
c.551A>T c.A551T Y184F 
c.553A>C c.A553C K185Q 
c.553A>G c.A553G K185E 
c.554A>C c.A554C K185T 
c.554A>T c.A554T K185M 
c.555G>C c.G555C K185N 
c.556C>A c.C556A H186N 
c.556C>G c.C556G H186D 
c.556C>T c.C556T H186Y 
c.557A>T c.A557T H186L 
c.558C>G c.C558G H186Q 
c.559_564dup c.559_564dup p.M187_S188dup 
c.559A>T c.A559T M187L 
c.559A>G c.A559G M187V 
c.560T>C c.T560C M187T 
c.561G>T or c.561G>A or 
c.561G>C 

c.G561T or c.G561A or c.G561C M187I 

c.562T>A c.T562A S188T 
c.562T>C c.T562C S188P 
c.562T>G c.T562G S188A 
c.563C>A c.C563A S188Y 
c.563C>G c.C563G S188C 
c.563C>T c.C563T S188F 
c.565T>G c.T565G L189V 
c.566T>C c.T566C L189S 
c.567G>C or c.567G>T c.G567C or c.G567T L189F 
c.568G>A c.G568A A190T 
c.568G>T c.G568T A190S 
c.569C>A c.C569A A190D 
c.569C>G c.C569G A190G 
c.569C>T c.C569T A190V 
c.571C>A c.C571A L191M 
c.571C>G c.C571G L191V 
c.572T>A c.T572A L191Q 



18 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.574A>C c.A574C N192H 
c.574A>G c.A574G N192D 
c.575A>C c.A575C N192T 
c.575A>G c.A575G N192S 
c.576T>A c.T576A N192K 
c.577A>G c.A577G R193G 
c.577A>T c.A577T R193W 
c.578G>C c.G578C R193T 
c.578G>T c.G578T R193M 
c.580A>C c.A580C T194P 
c.580A>G c.A580G T194A 
c.580A>T or c.581C>G c.A580T or c.C581G T194S 
c.581C>A c.C581A T194N 
c.581C>T c.C581T T194I 
c.583G>A c.G583A G195S 
c.583G>C c.G583C G195R 
c.583G>T c.G583T G195C 
c.584G>T c.G584T G195V 
c.586A>G c.A586G R196G 
c.587G>A c.G587A R196K 
c.587G>C c.G587C R196T 
c.587G>T c.G587T R196I 
c.589A>G c.A589G S197G 
c.589A>T c.A589T S197C 
c.590G>A c.G590A S197N 
c.590G>C c.G590C S197T 
c.590G>T c.G590T S197I 
c.593T>C c.T593C I198T 
c.593T>G c.T593G I198S 
c.594T>G c.T594G I198M 
c.595G>A c.G595A V199M 
c.595G>C c.G595C V199L 
c.596T>A c.T596A V199E 
c.596T>C c.T596C V199A 
c.596T>G c.T596G V199G 
c.598T>A c.T598A Y200N 
c.599A>C c.A599C Y200S 
c.599A>G c.A599G Y200C 
c.601T>A c.T601A S201T 
c.601T>G c.T601G S201A 
c.602C>A c.C602A S201Y 
c.602C>G c.C602G S201C 
c.602C>T c.C602T S201F 
c.607G>C c.G607C E203Q 
c.608A>C c.A608C E203A 
c.608A>G c.A608G E203G 
c.608A>T c.A608T E203V 
c.609G>C or c.609G>T c.G609C or c.G609T E203D 
c.610T>G c.T610G W204G 
c.611G>C c.G611C W204S 



19 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.611G>T c.G611T W204L 
c.613C>A c.C613A P205T 
c.613C>T c.C613T P205S 
c.614C>T c.C614T P205L 
c.616C>A c.C616A L206I 
c.616C>G c.C616G L206V 
c.616C>T c.C616T L206F 
c.617T>A c.T617A L206H 
c.617T>G c.T617G L206R 
c.619T>C c.T619C Y207H 
c.620A>C c.A620C Y207S 
c.620A>T c.A620T Y207F 
c.623T>A c.T623A M208K 
c.623T>G c.T623G M208R 
c.625T>A c.T625A W209R 
c.625T>G c.T625G W209G 
c.627G>C c.G627C W209C 
c.628C>A c.C628A P210T 
c.628C>T c.C628T P210S 
c.629C>A c.C629A P210H 
c.629C>T c.C629T P210L 
c.631T>C c.T631C F211L 
c.631T>G c.T631G F211V 
c.632T>A c.T632A F211Y 
c.632T>C c.T632C F211S 
c.632T>G c.T632G F211C 
c.635A>C c.A635C Q212P 
c.636A>T c.A636T Q212H 
c.637A>C c.A637C K213Q 
c.637A>G c.A637G K213E 
c.638A>G c.A638G K213R 
c.638A>T c.A638T K213M 
c.640C>A c.C640A P214T 
c.640C>G c.C640G P214A 
c.640C>T c.C640T P214S 
c.641C>A c.C641A P214H 
c.641C>G c.C641G P214R 
c.641C>T c.C641T P214L 
c.643A>C c.A643C N215H 
c.643A>G c.A643G N215D 
c.643A>T c.A643T N215Y 
c.644A>C c.A644C N215T 
c.644A>G c.A644G N215S 
c.[644A>G; 937G>T] c.A644G/G937T N215S/D313Y 
c.644A>T c.A644T N215I 
c.645T>A c.T645A N215K 
c.646T>A c.T646A Y216N 
c.646T>C c.T646C Y216H 
c.646T>G c.T646G Y216D 
c.647A>C c.A647C Y216S 



20 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.647A>G c.A647G Y216C 
c.647A>T c.A647T Y216F 
c.649A>C c.A649C T217P 
c.649A>G c.A649G T217A 
c.649A>T c.A649T T217S 
c.650C>A c.C650A T217K 
c.650C>G c.C650G T217R 
c.650C>T c.C650T T217I 
c.652G>A c.G652A E218K 
c.652G>C c.G652C E218Q 
c.653A>C c.A653C E218A 
c.653A>G c.A653G E218G 
c.653A>T c.A653T E218V 
c.654A>T c.A654T E218D 
c.655A>C c.A655C I219L 
c.655A>T c.A655T I219F 
c.656T>A c.T656A I219N 
c.656T>C c.T656C I219T 
c.656T>G c.T656G I219S 
c.657C>G c.C657G I219M 
c.659G>A c.G659A R220Q 
c.659G>C c.G659C R220P 
c.659G>T c.G659T R220L 
c.661C>A c.C661A Q221K 
c.661C>G c.C661G Q221E 
c.662A>C c.A662C Q221P 
c.662A>G c.A662G Q221R 
c.662A>T c.A662T Q221L 
c.663G>C c.G663C Q221H 
c.664T>A c.T664A Y222N 
c.664T>C c.T664C Y222H 
c.664T>G c.T664G Y222D 
c.665A>C c.A665C Y222S 
c.665A>G c.A665G Y222C 
c.670A>C c.A670C N224H 
c.671A>C c.A671C N224T 
c.671A>G c.A671G N224S 
c.673C>G c.C673G H225D 
c.679C>G c.C679G R227G 
c.682A>C c.A682C N228H 
c.682A>G c.A682G N228D 
c.683A>C c.A683C N228T 
c.683A>G c.A683G N228S 
c.683A>T c.A683T N228I 
c.685T>A c.T685A F229I 
c.686T>A c.T686A F229Y 
c.686T>C c.T686C F229S 
c.687T>A or c.687T>G c.T687A or c.T687G F229L 
c.688G>C c.G688C A230P 
c.689C>A c.C689A A230D 



21 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.689C>G c.C689G A230G 
c.689C>T c.C689T A230V 
c.694A>C c.A694C I232L 
c.694A>G c.A694G I232V 
c.695T>C c.T695C I232T 
c.696T>G c.T696G I232M 
c.698A>C c.A698C D233A 
c.698A>G c.A698G D233G 
c.698A>T c.A698T D233V 
c.699T>A c.T699A D233E 
c.703T>A c.T703A S235T 
c.703T>G c.T703G S235A 
c.710A>T c.A710T K237I 
c.712A>G c.A712G S238G 
c.712A>T c.A712T S238C 
c.713G>A c.G713A S238N 
c.713G>C c.G713C S238T 
c.713G>T c.G713T S238I 
c.715A>T c.A715T I239L 
c.716T>C c.T716C I239T 
c.717A>G c.A717G I239M 
c.718A>G c.A718G K240E 
c.719A>G c.A719G K240R 
c.719A>T c.A719T K240M 
c.720G>C or c.720G>T c.G720C or c.G720T K240N 
c.721A>T c.A721T S241C 
c.722G>C c.G722C S241T 
c.722G>T c.G722T S241I 
c.724A>C c.A724C I242L 
c.724A>G c.A724G I242V 
c.724A>T c.A724T I242F 
c.725T>A c.T725A I242N 
c.725T>C c.T725C I242T 
c.725T>G c.T725G I242S 
c.726C>G c.C726G I242M 
c.727T>A c.T727A L243M 
c.727T>G c.T727G L243V 
c.728T>C c.T728C L243S 
c.728T>G c.T728G L243W 
c.729G>C or c.729G>T c.G729C or c.G729T L243F 
c.730G>A c.G730A D244N 
c.730G>C c.G730C D244H 
c.730G>T c.G730T D244Y 
c.731A>C c.A731C D244A 
c.731A>G c.A731G D244G 
c.731A>T c.A731T D244V 
c.732C>G c.C732G D244E 
c.733T>G c.T733G W245G 
c.735G>C c.G735C W245C 
c.736A>G c.A736G T246A 



22 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.737C>A c.C737A T246K 
c.737C>G c.C737G T246R 
c.737C>T c.C737T T246I 
c.739T>A c.T739A S247T 
c.739T>G c.T739G S247A 
c.740C>A c.C740A S247Y 
c.740C>G c.C740G S247C 
c.740C>T c.C740T S247F 
c.742T>G c.T742G F248V 
c.743T>A c.T743A F248Y 
c.743T>G c.T743G F248C 
c.744T>A c.T744A F248L 
c.745A>C c.A745C N249H 
c.745A>G c.A745G N249D 
c.745A>T c.A745T N249Y 
c.746A>C c.A746C N249T 
c.746A>G c.A746G N249S 
c.746A>T c.A746T N249I 
c.747C>G or c.747C>A c.C747G or c.C747A N249K 
c.748C>A c.C748A Q250K 
c.748C>G c.C748G Q250E 
c.749A>C c.A749C Q250P 
c.749A>G c.A749G Q250R 
c.749A>T c.A749T Q250L 
c.750G>C c.G750C Q250H 
c.751G>A c.G751A E251K 
c.751G>C c.G751C E251Q 
c.752A>G c.A752G E251G 
c.752A>T c.A752T E251V 
c.754A>G c.A754G R252G 
c.757A>G c.A757G I253V 
c.757A>T c.A757T I253F 
c.758T>A c.T758A I253N 
c.758T>C c.T758C I253T 
c.758T>G c.T758G I253S 
c.760-762delGTT or c.761-763del c.760_762delGTT or 

c.761_763del 
p.V254del 

c.760G>T c.G760T V254F 
c.761T>A c.T761A V254D 
c.761T>C c.T761C V254A 
c.761T>G c.T761G V254G 
c.763G>A c.G763A D255N 
c.763G>C c.G763C D255H 
c.763G>T c.G763T D255Y 
c.764A>C c.A764C D255A 
c.764A>T c.A764T D255V 
c.765T>A c.T765A D255E 
c.766G>C c.G766C V256L 
c.767T>A c.T767A V256D 
c.767T>G c.T767G V256G 



23 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.769G>A c.G769A A257T 
c.769G>C c.G769C A257P 
c.769G>T c.G769T A257S 
c.770C>G c.C770G A257G 
c.770C>T c.C770T A257V 
c.772G>C or c.772G>A c.G772C or c.G772A G258R 
c.773G>A c.G773A G258E 
c.773G>T c.G773T G258V 
c.775C>A c.C775A P259T 
c.775C>G c.C775G P259A 
c.775C>T c.C775T P259S 
c.776C>A c.C776A P259Q 
c.776C>G c.C776G P259R 
c.776C>T c.C776T P259L 
c.778G>T c.G778T G260W 
c.779G>A c.G779A G260E 
c.779G>C c.G779C G260A 
c.781G>A c.G781A G261S 
c.781G>C c.G781C G261R 
c.781G>T c.G781T G261C 
c.782G>C c.G782C G261A 
c.787A>C c.A787C N263H 
c.788A>C c.A788C N263T 
c.788A>G c.A788G N263S 
c.790G>A c.G790A D264N 
c.790G>C c.G790C D264H 
c.790G>T c.G790T D264Y 
c.793C>G c.C793G P265A 
c.794C>A c.C794A P265Q 
c.794C>T c.C794T P265L 
c.799A>G c.A799G M267V 
c.799A>T c.A799T M267L 
c.800T>C c.T800C M267T 
c.802T>A c.T802A L268I 
c.804A>T c.A804T L268F 
c.805G>A c.G805A V269M 
c.805G>C c.G805C V269L 
c.806T>C c.T806C V269A 
c.808A>C c.A808C I270L 
c.808A>G c.A808G I270V 
c.809T>C c.T809C I270T 
c.809T>G c.T809G I270S 
c.810T>G c.T810G I270M 
c.811G>A c.G811A G271S 
c.[811G>A; 937G>T] c.G811A/G937T G271S/D313Y 
c.812G>A c.G812A G271D 
c.812G>C c.G812C G271A 
c.814A>G c.A814G N272D 
c.818T>A c.T818A F273Y 
c.823C>A c.C823A L275I 



24 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.823C>G c.C823G L275V 
c.827G>A c.G827A S276N 
c.827G>C c.G827C S276T 
c.829T>G c.T829G W277G 
c.830G>T c.G830T W277L 
c.831G>T or c.831G>C c.G831T or c.G831C W277C 
c.832A>T c.A832T N278Y 
c.833A>T c.A833T N278I 
c.835C>G c.C835G Q279E 
c.838C>A c.C838A Q280K 
c.839A>G c.A839G Q280R 
c.839A>T c.A839T Q280L 
c.840A>T or c.840A>C c.A840T or c.A840C Q280H 
c.841G>C c.G841C V281L 
c.842T>A c.T842A V281E 
c.842T>C c.T842C V281A 
c.842T>G c.T842G V281G 
c.844A>G c.A844G T282A 
c.844A>T c.A844T T282S 
c.845C>T c.C845T T282I 
c.847C>G c.C847G Q283E 
c.848A>T c.A848T Q283L 
c.849G>C c.G849C Q283H 
c.850A>G c.A850G M284V 
c.850A>T c.A850T M284L 
c.851T>C c.T851C M284T 
c.852G>C c.G852C M284I 
c.853G>A c.G853A A285T 
c.854C>G c.C854G A285G 
c.854C>T c.C854T A285V 
c.856C>G c.C856G L286V 
c.856C>T c.C856T L286F 
c.857T>A c.T857A L286H 
c.860G>T c.G860T W287L 
c.862G>C c.G862C A288P 
c.862G>T c.G862T A288S 
c.863C>G c.C863G A288G 
c.863C>T c.C863T A288V 
c.865A>C c.A865C I289L 
c.865A>G c.A865G I289V 
c.866T>C c.T866C I289T 
c.866T>G c.T866G I289S 
c.868A>C or c.868A>T c.A868C or c.A868T M290L 
c.868A>G c.A868G M290V 
c.869T>C c.T869C M290T 
c.870G>A or c.870G>C or 
c.870G>T 

c.G870A or c.G870C or c.G870T M290I 

c.871G>A c.G871A A291T 
c.871G>T c.G871T A291S 
c.872C>G c.C872G A291G 



25 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.874G>T c.G874T A292S 
c.875C>G c.C875G A292G 
c.877C>A c.C877A P293T 
c.880T>A c.T880A L294I 
c.880T>G c.T880G L294V 
c.881T>C c.T881C L294S 
c.882A>T c.A882T L294F 
c.883T>A c.T883A F295I 
c.883T>G c.T883G F295V 
c.884T>A c.T884A F295Y 
c.884T>C c.T884C F295S 
c.884T>G c.T884G F295C 
c.886A>G c.A886G M296V 
c.886A>T or c.886A>C c.A886T or c.A886C M296L 
c.887T>C c.T887C M296T 
c.888G>A or c.888G>T or 
c.888G>C 

c.G888A or c.G888T or c.G888C M296I 

c.889T>A c.T889A S297T 
c.892A>G c.A892G N298D 
c.893A>C c.A893C N298T 
c.893A>G c.A893G N298S 
c.893A>T c.A893T N298I 
c.895G>A c.G895A D299N 
c.895G>C c.G895C D299H 
c.897C>G or c.897C>A c.C897G or c.C897A D299E 
c.898C>A c.C898A L300I 
c.898C>G c.C898G L300V 
c.898C>T c.C898T L300F 
c.899T>C c.T899C L300P 
c.901C>G c.C901G R301G 
c.902G>A c.G902A R301Q 
c.902G>C c.G902C R301P 
c.902G>T c.G902T R301L 
c.904C>A c.C904A H302N 
c.904C>G c.C904G H302D 
c.904C>T c.C904T H302Y 
c.905A>T c.A905T H302L 
c.907A>G c.A907G I303V 
c.907A>T c.A907T I303F 
c.908T>A c.T908A I303N 
c.908T>C c.T908C I303T 
c.908T>G c.T908G I303S 
c.911G>A c.G911A S304N 
c.911G>C c.G911C S304T 
c.911G>T c.G911T S304I 
c.916C>G c.C916G Q306E 
c.917A>C c.A917C Q306P 
c.917A>T c.A917T Q306L 
c.919G>A c.G919A A307T 
c.919G>C c.G919C A307P 



26 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.919G>T c.G919T A307S 
c.920C>A c.C920A A307D 
c.920C>G c.C920G A307G 
c.920C>T c.C920T A307V 
c.922A>C c.A922C K308Q 
c.922A>G c.A922G K308E 
c.923A>G c.A923G K308R 
c.923A>T c.A923T K308I 
c.924A>T or c.924A>C c.A924T or c.A924C K308N 
c.925G>A c.G925A A309T 
c.925G>C c.G925C A309P 
c.926C>A c.C926A A309D 
c.926C>T c.C926T A309V 
c.928C>A c.C928A L310I 
c.928C>G c.C928G L310V 
c.928C>T c.C928T L310F 
c.931C>A c.C931A L311I 
c.931C>G c.C931G L311V 
c.934C>A c.C934A Q312K 
c.934C>G c.C934G Q312E 
c.935A>G c.A935G Q312R 
c.935A>T c.A935T Q312L 
c.936G>T or c.936G>C c.G936T or c.G936C Q312H 
c.937G>T c.G937T D313Y 
c.[937G>T; 1232G>A] c.G937T/G1232A D313Y/G411D 
c.938A>G c.A938G D313G 
c.938A>T c.A938T D313V 
c.939T>A c.T939A D313E 
c.940A>G c.A940G K314E 
c.941A>C c.A941C K314T 
c.941A>T c.A941T K314M 
c.942G>C c.G942C K314N 
c.943G>A c.G943A D315N 
c.943G>C c.G943C D315H 
c.943G>T c.G943T D315Y 
c.944A>C c.A944C D315A 
c.944A>G c.A944G D315G 
c.944A>T c.A944T D315V 
c.946G>A c.G946A V316I 
c.946G>C c.G946C V316L 
c.947T>C c.T947C V316A 
c.947T>G c.T947G V316G 
c.949A>C c.A949C I317L 
c.949A>G c.A949G I317V 
c.950T>C c.T950C I317T 
c.951T>G c.T951G I317M 
c.952G>A c.G952A A318T 
c.952G>C c.G952C A318P 
c.953C>A c.C953A A318D 
c.953C>T c.C953T A318V 



27 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.955A>T c.A955T I319F 
c.956T>C c.T956C I319T 
c.957C>G c.C957G I319M 
c.958A>C c.A958C N320H 
c.959A>C c.A959C N320T 
c.959A>G c.A959G N320S 
c.959A>T c.A959T N320I 
c.961C>A c.C961A Q321K 
c.962A>G c.A962G Q321R 
c.962A>T c.A962T Q321L 
c.963G>C or c.963G>T c.G963C or c.G963T Q321H 
c.964G>A c.G964A D322N 
c.964G>C c.G964C D322H 
c.965A>C c.A965C D322A 
c.965A>T c.A965T D322V 
c.966C>A or c.966C>G c.C966A or c.C966G D322E 
c.967C>A c.C967A P323T 
c.968C>G c.C968G P323R 
c.970T>G c.T970G L324V 
c.971T>G c.T971G L324W 
c.973G>A c.G973A G325S 
c.973G>C c.G973C G325R 
c.973G>T c.G973T G325C 
c.974G>C c.G974C G325A 
c.974G>T c.G974T G325V 
c.976A>C c.A976C K326Q 
c.976A>G c.A976G K326E 
c.977A>C c.A977C K326T 
c.977A>G c.A977G K326R 
c.977A>T c.A977T K326M 
c.978G>C or c.978G>T c.G978C or c.G978T K326N 
c.979C>G c.C979G Q327E 
c.980A>C c.A980C Q327P 
c.980A>T c.A980T Q327L 
c.981A>T c.A981T Q327H 
c.983G>C c.G983C G328A 
c.985T>A c.T985A Y329N 
c.985T>C c.T985C Y329H 
c.985T>G c.T985G Y329D 
c.986A>G c.A986G Y329C 
c.986A>T c.A986T Y329F 
c.988C>A c.C988A Q330K 
c.988C>G c.C988G Q330E 
c.989A>C c.A989C Q330P 
c.989A>G c.A989G Q330R 
c.990G>C c.G990C Q330H 
c.991C>G c.C991G L331V 
c.992T>A c.T992A L331H 
c.992T>C c.T992C L331P 
c.992T>G c.T992G L331R 



28 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.994A>G c.A994G R332G 
c.995G>C c.G995C R332T 
c.995G>T c.G995T R332I 
c.996A>T c.A996T R332S 
c.997C>G c.C997G Q333E 
c.998A>C c.A998C Q333P 
c.998A>T c.A998T Q333L 
c.1000G>C c.G1000C G334R 
c.1001G>A c.G1001A G334E 
c.1001G>T c.G1001T G334V 
c.1003G>T c.G1003T D335Y 
c.1004A>C c.A1004C D335A 
c.1004A>G c.A1004G D335G 
c.1004A>T c.A1004T D335V 
c.1005C>G c.C1005G D335E 
c.1006A>G c.A1006G N336D 
c.1006A>T c.A1006T N336Y 
c.1007A>C c.A1007C N336T 
c.1007A>G c.A1007G N336S 
c.1007A>T c.A1007T N336I 
c.1009T>G c.T1009G F337V 
c.1010T>A c.T1010A F337Y 
c.1010T>C c.T1010C F337S 
c.1010T>G c.T1010G F337C 
c.1011T>A c.T1011A F337L 
c.1012G>A c.G1012A E338K 
c.1013A>C c.A1013C E338A 
c.1013A>G c.A1013G E338G 
c.1013A>T c.A1013T E338V 
c.1014A>T c.A1014T E338D 
c.1015G>A c.G1015A V339M 
c.1016T>A c.T1016A V339E 
c.1016T>C c.T1016C V339A 
c.1021G>C c.G1021C E341Q 
c.1022A>C c.A1022C E341A 
c.1027C>A c.C1027A P343T 
c.1027C>G c.C1027G P343A 
c.1027C>T c.C1027T P343S 
c.1028C>T c.C1028T P343L 
c.1030C>G c.C1030G L344V 
c.1030C>T c.C1030T L344F 
c.1031T>G c.T1031G L344R 
c.1033T>C c.T1033C S345P 
c.1036G>T c.G1036T G346C 
c.1037G>A c.G1037A G346D 
c.1037G>C c.G1037C G346A 
c.1037G>T c.G1037T G346V 
c.1039T>A c.T1039A L347I 
c.1043C>A c.C1043A A348D 
c.1046G>C c.G1046C W349S 



29 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1046G>T c.G1046T W349L 
c.1047G>C c.G1047C W349C 
c.1048G>A c.G1048A A350T 
c.1048G>T c.G1048T A350S 
c.1049C>G c.C1049G A350G 
c.1049C>T c.C1049T A350V 
c.1052T>A c.T1052A V351E 
c.1052T>C c.T1052C V351A 
c.1054G>A c.G1054A A352T 
c.1054G>T c.G1054T A352S 
c.1055C>G c.C1055G A352G 
c.1055C>T c.C1055T A352V 
c.1057A>T c.A1057T M353L 
c.1058T>A c.T1058A M353K 
c.1058T>C c.T1058C M353T 
c.1061T>A c.T1061A I354K 
c.1061T>G c.T1061G I354R 
c.1063A>C c.A1063C N355H 
c.1063A>G c.A1063G N355D 
c.1063A>T c.A1063T N355Y 
c.1064A>G c.A1064G N355S 
c.1066C>G c.C1066G R356G 
c.1066C>T c.C1066T R356W 
c.1067G>A c.G1067A R356Q 
c.1067G>C c.G1067C R356P 
c.1067G>T c.G1067T R356L 
c.1069C>G c.C1069G Q357E 
c.1072G>C c.G1072C E358Q 
c.1073A>C c.A1073C E358A 
c.1073A>G c.A1073G E358G 
c.1074G>T or c.1074G>C c.G1074T or c.G1074C E358D 
c.1075A>C c.A1075C I359L 
c.1075A>G c.A1075G I359V 
c.1075A>T c.A1075T I359F 
c.1076T>A c.T1076A I359N 
c.1076T>C c.T1076C I359T 
c.1076T>G c.T1076G I359S 
c.1078G>A c.G1078A G360S 
c.1078G>C c.G1078C G360R 
c.1078G>T c.G1078T G360C 
c.1079G>A c.G1079A G360D 
c.1079G>C c.G1079C G360A 
c.1082G>A c.G1082A G361E 
c.1082G>C c.G1082C G361A 
c.1084C>A c.C1084A P362T 
c.1084C>G c.C1084G P362A 
c.1084C>T c.C1084T P362S 
c.1085C>A c.C1085A P362H 
c.1085C>G c.C1085G P362R 
c.1085C>T c.C1085T P362L 



30 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1087C>A c.C1087A R363S 
c.1087C>G c.C1087G R363G 
c.1087C>T c.C1087T R363C 
c.1088G>A c.G1088A R363H 
c.1088G>T c.G1088T R363L 
c.1090T>C c.T1090C S364P 
c.1091C>G c.C1091G S364C 
c.1093T>A c.T1093A Y365N 
c.1093T>G c.T1093G Y365D 
c.1094A>C c.A1094C Y365S 
c.1094A>T c.A1094T Y365F 
c.1096A>C c.A1096C T366P 
c.1096A>T c.A1096T T366S 
c.1097C>A c.C1097A T366N 
c.1097C>T c.C1097T T366I 
c.1099A>C c.A1099C I367L 
c.1099A>T c.A1099T I367F 
c.1101C>G c.C1101G I367M 
c.1102G>A c.G1102A A368T 
c.1102G>C c.G1102C A368P 
c.1103C>G c.C1103G A368G 
c.1105G>A c.G1105A V369I 
c.1105G>C c.G1105C V369L 
c.1105G>T c.G1105T V369F 
c.1106T>C c.T1106C V369A 
c.1106T>G c.T1106G V369G 
c.1108G>A c.G1108A A370T 
c.1108G>C c.G1108C A370P 
c.1109C>A c.C1109A A370D 
c.1109C>G c.C1109G A370G 
c.1109C>T c.C1109T A370V 
c.1111T>A c.T1111A S371T 
c.1112C>G c.C1112G S371C 
c.1117G>A c.G1117A G373S 
c.1117G>T c.G1117T G373C 
c.1118G>C c.G1118C G373A 
c.1120A>G c.A1120G K374E 
c.1121A>C c.A1121C K374T 
c.1121A>G c.A1121G K374R 
c.1121A>T c.A1121T K374I 
c.1123G>C c.G1123C G375R 
c.1124G>A c.G1124A G375E 
c.1124G>C c.G1124C G375A 
c.1126G>A c.G1126A V376M 
c.1126G>C c.G1126C V376L 
c.1127T>A c.T1127A V376E 
c.1127T>G c.T1127G V376G 
c.1129G>A c.G1129A A377T 
c.1129G>C c.G1129C A377P 
c.1129G>T c.G1129T A377S 



31 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1130C>G c.C1130G A377G 
c.1135A>G c.A1135G N379D 
c.1136A>C c.A1136C N379T 
c.1136A>T c.A1136T N379I 
c.1137T>A c.T1137A N379K 
c.1138C>A c.C1138A P380T 
c.1138C>G c.C1138G P380A 
c.1139C>A c.C1139A P380H 
c.1139C>G c.C1139G P380R 
c.1139C>T c.C1139T P380L 
c.1142C>A c.C1142A A381D 
c.1147T>A c.T1147A F383I 
c.1148T>A c.T1148A F383Y 
c.1148T>G c.T1148G F383C 
c.1150A>T c.A1150T I384F 
c.1151T>C c.T1151C I384T 
c.1152C>G c.C1152G I384M 
c.1153A>G c.A1153G T385A 
c.1154C>T c.C1154T T385I 
c.1156C>A c.C1156A Q386K 
c.1157A>T c.A1157T Q386L 
c.1158G>C c.G1158C Q386H 
c.1159C>A c.C1159A L387I 
c.1159C>T c.C1159T L387F 
c.1160T>A c.T1160A L387H 
c.1160T>G c.T1160G L387R 
c.1162C>A c.C1162A L388I 
c.1162C>G c.C1162G L388V 
c.1162C>T c.C1162T L388F 
c.1163T>A c.T1163A L388H 
c.1163T>G c.T1163G L388R 
c.1168G>A c.G1168A V390M 
c.1171A>C c.A1171C K391Q 
c.1171A>G c.A1171G K391E 
c.1172A>C c.A1172C K391T 
c.1172A>G c.A1172G K391R 
c.1172A>T c.A1172T K391I 
c.1173A>T c.A1173T K391N 
c.1174A>G c.A1174G R392G 
c.1174A>T c.A1174T R392W 
c.1175G>A c.G1175A R392K 
c.1175G>C c.G1175C R392T 
c.1175G>T c.G1175T R392M 
c.1177A>C c.A1177C K393Q 
c.1177A>G c.A1177G K393E 
c.1178A>C c.A1178C K393T 
c.1179G>C c.G1179C K393N 
c.1180C>A c.C1180A L394I 
c.1181T>A c.T1181A L394Q 
c.1181T>C c.T1181C L394P 



32 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1181T>G c.T1181G L394R 
c.1183G>C c.G1183C G395R 
c.1184G>A c.G1184A G395E 
c.1184G>C c.G1184C G395A 
c.1186T>A c.T1186A F396I 
c.1186T>G c.T1186G F396V 
c.1187T>G c.T1187G F396C 
c.1188C>G c.C1188G F396L 
c.1189T>A c.T1189A Y397N 
c.1189T>C c.T1189C Y397H 
c.1190A>C c.A1190C Y397S 
c.1190A>G c.A1190G Y397C 
c.1190A>T c.A1190T Y397F 
c.1192G>A c.G1192A E398K 
c.1192G>C c.G1192C E398Q 
c.1193A>G c.A1193G E398G 
c.1195T>A c.T1195A W399R 
c.1195T>G c.T1195G W399G 
c.1198A>C c.A1198C T400P 
c.1198A>G c.A1198G T400A 
c.1198A>T c.A1198T T400S 
c.1199C>A c.C1199A T400N 
c.1199C>T c.C1199T T400I 
c.1201T>A c.T1201A S401T 
c.1201T>G c.T1201G S401A 
c.1202_1203insGACTTC c.1202_1203insGACTTC p.T400_S401dup 
c.1202C>T c.C1202T S401L 
c.1204A>G c.A1204G R402G 
c.1204A>T c.A1204T R402W 
c.1205G>C c.G1205C R402T 
c.1205G>T c.G1205T R402M 
c.1206G>C c.G1206C R402S 
c.1207T>G c.T1207G L403V 
c.1208T>C c.T1208C L403S 
c.1209A>T c.A1209T L403F 
c.1210A>G c.A1210G R404G 
c.1211G>A c.G1211A R404K 
c.1211G>C c.G1211C R404T 
c.1211G>T c.G1211T R404I 
c.1212A>T c.A1212T R404S 
c.1213A>G c.A1213G S405G 
c.1216C>G c.C1216G H406D 
c.1217A>T c.A1217T H406L 
c.1218C>G c.C1218G H406Q 
c.1219A>T c.A1219T I407L 
c.1220T>C c.T1220C I407T 
c.1221A>G c.A1221G I407M 
c.1222A>C c.A1222C N408H 



33 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1222A>G c.A1222G N408D 
c.1222A>T c.A1222T N408Y 
c.1223A>C c.A1223C N408T 
c.1225C>A c.C1225A P409T 
c.1225C>G c.C1225G P409A 
c.1225C>T c.C1225T P409S 
c.1226C>T c.C1226T P409L 
c.1228A>G c.A1228G T410A 
c.1228A>T c.A1228T T410S 
c.1229C>T c.C1229T T410I 
c.1231G>A c.G1231A G411S 
c.1231G>T c.G1231T G411C 
c.1232G>A c.G1232A G411D 
c.1232G>C c.G1232C G411A 
c.1232G>T c.G1232T G411V 
c.1234A>C c.A1234C T412P 
c.1234A>G c.A1234G T412A 
c.1234A>T c.A1234T T412S 
c.1235C>A c.C1235A T412N 
c.1235C>T c.C1235T T412I 
c.1237G>A c.G1237A V413I 
c.1237G>T c.G1237T V413F 
c.1238T>G c.T1238G V413G 
c.1240T>G c.T1240G L414V 
c.1242G>C c.G1242C L414F 
c.1243C>A c.C1243A L415I 
c.1244T>A c.T1244A L415H 
c.1246C>G c.C1246G Q416E 
c.1247A>T c.A1247T Q416L 
c.1248G>C c.G1248C Q416H 
c.1249C>A c.C1249A L417I 
c.1252G>A c.G1252A E418K 
c.1252G>C c.G1252C E418Q 
c.1253A>C c.A1253C E418A 
c.1253A>G c.A1253G E418G 
c.1254A>T c.A1254T E418D 
c.1255A>G c.A1255G N419D 
c.1255A>T c.A1255T N419Y 
c.1256A>C c.A1256C N419T 
c.1256A>G c.A1256G N419S 
c.1256A>T c.A1256T N419I 
c.1258A>C c.A1258C T420P 
c.1258A>T c.A1258T T420S 
c.1259C>A c.C1259A T420K 
c.1259C>G c.C1259G T420R 
c.1261A>G c.A1261G M421V 
c.1261A>T c.A1261T M421L 
c.1262T>A c.T1262A M421K 
c.1262T>C c.T1262C M421T 
c.1262T>G c.T1262G M421R 



34 

Table 2: Galafold (migalastat) amenability table 

Nucleotide change Nucleotide change Protein sequence change 

c.1263G>C c.G1263C M421I 
c.1265A>C c.A1265C Q422P 
c.1267A>T c.A1267T M423L 
c.1268T>A c.T1268A M423K 
c.1268T>C c.T1268C M423T 
c.1269G>C c.G1269C M423I 
c.1271C>T c.C1271T S424L 
c.1275A>C c.A1275C L425F 
c.1279G>A c.G1279A D427N 
c.1286T>G c.T1286G L429R 

 
Pharmacodynamic effects 
 
Treatment with Galafold in Phase 2 pharmacodynamic trials generally resulted in increases in 
endogenous α-Gal A activity in WBCs, as well as in skin and kidney for the majority of patients. In 
patients with amenable mutations, GL-3 levels tended to decrease in urine and in kidney interstitial 
capillaries. 
 
Clinical efficacy and safety 
 
The clinical efficacy and safety of Galafold have been evaluated in two Phase 3 pivotal trials and two 
open-label extension (OLE) trials. All patients received the recommended dosage of 123 mg Galafold 
every other day.  
 
The first Phase 3 trial (ATTRACT) was a randomised open-label active comparator trial that evaluated 
the efficacy and safety of Galafold compared to enzyme replacement therapy (ERT) (agalsidase beta, 
agalsidase alfa) in 52 male and female patients with Fabry disease who were receiving ERT prior to 
trial entry and who have amenable mutations (ERT-experienced trial). The study was structured in two 
periods. During the first period (18-months) ERT-experienced patients were randomised to switch 
from ERT to Galafold or continue with ERT. The second period was an optional 12-month open-label 
extension in which all subjects received Galafold. 
 
The second Phase 3 trial (FACETS) was a 6-month randomised double-blind placebo-controlled trial 
(through month 6) with an 18-month open-label period to evaluate the efficacy and safety of Galafold 
in 50 male and female patients with Fabry disease who were naïve to ERT, or had previously been on 
ERT and had stopped for at least 6 months and who have amenable mutations (ERT-naïve trial).  
 
The first OLE trial (AT1001-041) included patients from Phase 2 and Phase 3 studies and has 
completed. The mean extent of exposure to the marketed dose of Galafold 123 mg QOD in patients 
completing study AT1001-041 was 3.57 (±1.23) years (n=85). The maximum exposure was 5.6 years. 
 
The second OLE trial (AT1001-042) included patients that both transferred from OLE study 
AT1001-041 and directly from Phase 3 study ATTRACT, and is ongoing. 
 
Renal Function  
In the ERT-experienced trial, renal function remained stable for up to 18 months of treatment with 
Galafold. Mean annualised rate of change in eGFRCKD-EPI was -0.40 mL/min/1.73 m2 (95% CI: -2.272, 
1.478; n=34) in the Galafold group compared to -1.03 mL/min/1.73 m2 (95% CI: -3.636, 1.575; n=18) 
in the ERT group. The mean annualised rate of change from baseline in eGFRCKD-EPI in patients treated 
for 30 months with Galafold was -1.72 mL/min/1.73 m2 (95% CI: -2.653, -0.782; n=31). 
 



35 

In the ERT-naïve trial and open-label extension, renal function remained stable for up to 5 years of 
treatment with Galafold. After an average of 3.4 years of treatment, the mean annualised rate of 
change in eGFRCKD-EPI was -0.74 mL/min/1.73 m2 (95% CI: -1.89, 0.40; n=41). No clinically 
significant differences were observed during the initial 6-month placebo-controlled period. 
 
Left Ventricular Mass Index (LVMi)  
In the ERT-experienced trial, following 18 months of treatment with Galafold there was a statistically 
significant decrease in LVMi (p<0.05). The baseline values were 95.3 g/m2 for the Galafold arm and 
92.9 g/m2 for the ERT arm and the mean change from baseline in LVMi at Month 18 was  
-6.6 (95% CI: -11.0, -2.1; n=31) for Galafold and -2.0 (95% CI: -11.0, 7.0; n=13) for ERT. The change 
from baseline to Month 18 in LVMi (g/m2) in patients with left ventricular hypertrophy (females with 
baseline LVMi >95 g/m2 and males with baseline LVMi >115 g/m2) was -8.4 (95% CI: -15.7, 2.6; 
n=13) for migalastat and 4.5 (95% CI: -10.7, 18.4; n=5) for ERT. After 30 months treatment with 
Galafold, the mean change from baseline in LVMi was -3.8 (95% CI: -8.9, 1.3; n=28) and the mean 
change from baseline in LVMi in patients with left ventricular hypertrophy at baseline was  
-10.0 (95% CI: -16.6, -3.3; n=10). 
 
In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p<0.05); the 
mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27). After 
follow up in the OLE, the mean change from baseline in LVMi at Month 36 was -8.3 (95% CI: -17.1, 
0.4; n=25) and at Month 48 was -9.1 (95% CI: -20.3, 2.0; n=18). The mean change from baseline in 
LVMi at Month 18 to 24 in patients with left ventricular hypertrophy at baseline (females with 
baseline LVMi >95 g/m2 or males with baseline LVMi >115 g/m2) was -18.6 (95% CI: -38.2, 1.0; 
n=8). After follow up in the OLE, the mean change from baseline in LVMi in patients with left 
ventricular hypertrophy at baseline at Month 36 was -30.0 (95%) CI: -57.9, -2.2; n=4) and at Month 48 
was -33.1 (CI: -60.9, -5.4; n=4). No clinically significant differences in LVMi were observed during 
the initial 6-month placebo-controlled period. 
 
Disease Substrate 
In the ERT-experienced trial, plasma lyso-Gb3 levels slightly increased but remained low in patients 
with amenable mutations treated with Galafold for the 30 month duration of the study. Plasma 
lyso-Gb3 levels also remained low in patients on ERT for up to 18 months. 
 
In the ERT- naïve trial, Galafold showed statistically significant reductions in plasma lyso-Gb3 
concentrations and kidney interstitial capillary GL-3 inclusions in patients with amenable mutations. 
Patients randomised to Galafold in Stage 1 demonstrated statistically significant greater reduction 
(±SEM) in mean interstitial capillary GL-3 deposition (-0.25±0.10; -39%) at month 6 compared to 
placebo (+0.07 ± 0.13; +14%) (p=0.008). Patients randomised to placebo in Stage 1 and switched to 
Galafold at month 6 (Stage 2) also demonstrated statistically significant decreases in interstitial 
capillary GL-3 inclusions at month 12 (-0.33±0.15; -58%) (p=0.014). Qualitative reductions in GL-3 
levels were observed in multiple renal cell types: podocytes, mesangial cells, and glomerular 
endothelial cells, respectively, over 12 months of treatment with Galafold.  
 
Composite Clinical Outcomes 
In the ERT-experienced trial, an analysis of a composite clinical outcome composed of renal, cardiac, 
and cerebrovascular events, or death, showed that the frequency of events observed in the Galafold 
treatment group was 29% compared to 44% in the ERT group over 18 months. The frequency of 
events in patients treated with Galafold over 30 months (32%) was similar to the 18 month period.  
 
Patient-Reported Outcome - Gastrointestinal Symptoms Rating Scale 
In the ERT-naïve trial, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that 
treatment with Galafold was associated with statistically significant (p<0.05) improvements versus 
placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with 
symptoms at baseline. During the open-label extension, statistically significant (p<0.05) improvements 
from baseline were observed in the diarrhoea and indigestion domains, with a trend of improvement in 
the constipation domain. 



36 

 
Paediatric population 
 
The European Medicines Agency has deferred the obligation to submit the results of studies with 
Galafold in one or more subsets of the paediatric population in the treatment of Fabry disease (see 
section 4.2 for information on paediatric use). 
 
5.2 Pharmacokinetic properties 
 
Absorption 
 
The absolute bioavailability (AUC) for a single oral 150 mg migalastat hydrochloride dose or a single 
2-hour 150 mg intravenous infusion was approximately 75%. Following a single oral dose of 150 mg 
migalastat hydrochloride solution, the time to peak plasma concentration was approximately 3 hours. 
Plasma migalastat exposure (AUC0-∞) and Cmax demonstrated dose-proportional increases at migalastat 
hydrochloride oral doses from 50 mg to 1,250 mg. 
 
Migalastat administered with a high-fat meal, or 1 hour before a high-fat or light meal, or 1 hour after 
a light meal, resulted in significant reductions of 37% to 42% in mean total migalastat exposure 
(AUC0-∞) and reductions of 15% to 40% in mean peak migalastat exposure (Cmax) compared with the 
fasting state (see section 4.2).  
 
Distribution 
 
In healthy volunteers, the volume of distribution (Vz/F) of migalastat following ascending single oral 
doses (25-675 mg migalastat HCl) ranged from 77 to 133 L, indicating it is well distributed into 
tissues and greater than total body water (42 litres). There was no detectable plasma protein binding 
following administration of [14C]-migalastat hydrochloride in the concentration range between 1 and 
100 µM. 
 
Biotransformation 
 
Based upon in vivo data, migalastat is a substrate for UGT, being a minor elimination pathway. 
Migalastat is not a substrate for P-glycoprotein (P-gP) in vitro and it is considered unlikely that 
migalastat would be subject to drug-drug interactions with cytochrome P450s. A pharmacokinetic trial 
in healthy male volunteers with 150 mg [14C]-migalastat HCl revealed that 99% of the radiolabeled 
dose recovered in plasma was comprised of unchanged migalastat (77%) and 3 dehydrogenated 
O-glucuronide conjugated metabolites, M1to M3 (13%). Approximately 9% of the total radioactivity 
was unassigned.  
 
Elimination 
 
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat hydrochloride 
revealed that approximately 77% of the radiolabeled dose was recovered in urine of which 55% of was 
excreted as unchanged migalastat and 4% as combined metabolites M1, M2 and M3. Approximately 
5% of the total sample radioactivity was unassigned components. Approximately 20% of the total 
radiolabeled dose was excreted in faeces, with unchanged migalastat being the only measured 
component. 
 
Following ascending single oral doses (25-675 mg migalastat hydrochloride), no trends were found for 
clearance, CL/F). At the 150 mg dose, CL/F was approximately 11 to 14 L/hr. Following 
administration of the same doses, the mean elimination half-life (t1/2) ranged from approximately 3 to 
5 hours.  
 



37 

Special populations 
 
Patients with renal impairment 
Galafold has not been studied in patients with Fabry disease who have a GFR less than 
30 mL/min/1.73 m2. In a single dose study with Galafold in non-Fabry subjects with varying degrees 
of renal insufficiency, exposures were increased by 4.3-fold in subjects with severe renal impairment 
(GFR < 30 mL/min/1.73 m2).  
 
Patients with hepatic impairment 
No studies have been carried out in subjects with impaired hepatic function. From the metabolism and 
excretion pathways, it is not expected that a decreased hepatic function may affect the 
pharmacokinetics of migalastat. 
 
Elderly (>65 years) 
Clinical studies of Galafold included small number of patients aged 65 and over. The effect of age was 
evaluated in a population pharmacokinetic analysis on plasma migalastat clearance in the ERT-naïve 
study population. The difference in clearance between Fabry patients ≥65 years and those <65 years 
was 20%, which was not considered clinically significant. 
 
Gender 
The pharmacokinetic characteristics of migalastat were not significantly different between females and 
males in either healthy volunteers or in patients with Fabry disease. 
 
5.3 Preclinical safety data 

Non-clinical studies suggest no specific hazard for humans on the basis of single-and repeat-dose 
studies, with the exception of transient and fully reversible infertility in male rats associated with 
migalastat treatment. The infertility associated with migalastat treatment was reported at clinically 
relevant exposures. Complete reversibility was seen after 4 weeks off-dose. Similar findings have been 
noted pre-clinically following treatment with other iminosugars. In the rabbit embryo-foetal toxicity 
study, findings including embryo-foetal death, a reduction in mean foetal weight, retarded ossification, 
and slightly increased incidences of minor skeletal abnormalities were observed only at doses 
associated with maternal toxicity. 
 
In a rat 104-week carcinogenicity study, there was an increased incidence of pancreatic islet cell 
adenomas in males at a dose level 19-fold higher than the exposure (AUC) at the clinically efficacious 
dose. This is a common spontaneous tumour in ad libitum-fed male rats. In the absence of similar 
findings in females, no findings in the genotoxicity battery or in the carcinogenicity study with 
Tg.rasH2 mice, and no pre-neoplastic pancreatic findings in the rodents or monkeys, this observation 
in male rats is not considered related to treatment and its relevance to humans is unknown.  
 
 
6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 

 
Capsule contents 
Pregelatinised starch (maize) 
Magnesium stearate 
 
Capsule shell 
Gelatin 
Titanium dioxide (E171) 
Indigotine (E132) 
 



38 

Printing ink 
Shellac 
Black iron oxide 
Potassium hydroxide 
 
6.2 Incompatibilities 
 
Not applicable.  
 
6.3 Shelf life 
 
4 years 
 
6.4 Special precautions for storage 
 
This medicinal product does not require any special temperature storage conditions. Store in the 
original package in order to protect from moisture. 
 
6.5 Nature and contents of container  
 
PVC / PCTFE / PVC/Al blister. 
Pack size of 14 capsules.  
 
6.6 Special precautions for disposal  
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Amicus Therapeutics Europe Limited  
Block 1, Blanchardstown Corporate Park 
Ballycoolin Road 
Blanchardstown, Dublin  
D15 AKK1 
Ireland 
Tel: +353 (0) 1 588 0836 
Fax: +353 (0) 1 588 6851 
e-mail: info@amicusrx.co.uk 
 
 
8. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/15/1082/001 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
26 May 2016 
 
 



39 

10. DATE OF REVISION OF THE TEXT 
 
DD month YYYY 

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu.

http://www.ema.europa.eu/


40 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE  

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 
 

 



41 

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 

Name and address of the manufacturer(s) responsible for batch release 

Almac Pharma Services (Ireland) Limited 

Finnabair Industrial Estate 

Dundalk, Co. Louth 

A91 P9KD 

Ireland 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 

Characteristics, section 4.2). 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION  

 

• Periodic safety update reports  
 

The requirements for submission of periodic safety update reports for this medicinal product are set 

out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 

2001/83/EC and any subsequent updates published on the European medicines web-portal. 

The marketing authorisation holder shall submit the first periodic safety update report for this 

product within 6 months following authorisation. 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

• Risk Management Plan (RMP) 
 

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the 

agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent 

updates of the RMP. 

An updated RMP should be submitted: 

• At the request of the European Medicines Agency; 

• Whenever the risk management system is modified, especially as the result of new 
information being received that may lead to a significant change to the benefit/risk profile or 

as the result of an important (pharmacovigilance or risk minimisation) milestone being 

reached. 

 

 

 



42 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III 
 

LABELLING AND PACKAGE LEAFLET 
 



43 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
A. LABELLING 

 



44 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING  
 
OUTER CARTON 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Galafold 123 mg hard capsules 
migalastat 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat  
 
 
3. LIST OF EXCIPIENTS 
 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
14 hard capsules  
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Do not eat food at least 2 hours before and 2 hours after taking your medicine to give a minimum 
4 hours fast. Take at the same time each day. 
Swallow the capsule whole. Do not cut, crush, or chew the capsule. 
Read the package leaflet before use. 
Oral use.  
 
Take Galafold capsule every other day and punch out the perforated circle on the blister sleeve on the 
days you are not taking Galafold.  
 
How to Remove a Capsule 
 

 

1. PRESS and hold purple tab, and PULL out card 
on the right (Figure 1). Unfold the card. 

2. Turn the card over showing the back side of the 
card. 
BEND card (Figure 2) to help raise perforations. 

3. REMOVE the oval perforated cardboard 
(Figure 3). 

4. Turn the card over showing the front side of the 
card. Push capsule out (Figure 4). 

  

 



45 

To access the package leaflet, scan the code below.  
QR code to be included + www.galafoldsmpc.co.uk 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children. 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
 
8. EXPIRY DATE 
 
EXP 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in the original package in order to protect from moisture.  
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 
 
 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Amicus Therapeutics Europe Limited 
Block 1, Blanchardstown Corporate Park 
Ballycoolin Road 
Blanchardstown, Dublin  
D15 AKK1 
Ireland 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/15/1082/001  
 
 
13. BATCH NUMBER 
 
Lot 
 
 

http://www.galafoldsmpc.co.uk/


46 

14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
 
15. INSTRUCTIONS ON USE 
 
 
 
16. INFORMATION IN BRAILLE 
 
galafold 123 mg hard capsules  
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 
<2D barcode carrying the unique identifier included.> 
 
 
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 
 
PC: {number} 
SN: {number}  
NN: {number}  
 



47 

MINIMUM PARTICULARS TO APPEAR ON INTERMEDIATE PACKAGING 
 
BLISTER SLEEVE 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Galafold 123 mg hard capsules  
migalastat 
 
 
2. NAME OF THE MARKETING AUTHORISATION HOLDER 
 
Amicus Therapeutics Europe Limited  
 
 
3. EXPIRY DATE 
 
EXP:  
 
 
4. BATCH NUMBER 
 
LOT: 
 
 
5. OTHER 
 
See package leaflet for further instructions. 
 
Punch out the perforated circles on days you are not taking Galafold. 
 
Galafold is to be taken every other day.  
 
Starting date: 



48 

 
MINIMUM PARTICULARS TO APPEAR ON INTERMEDIATE PACKAGING 
 
BLISTER FOIL 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
 
 
2. NAME OF THE MARKETING AUTHORISATION HOLDER 
 
 
 
3. EXPIRY DATE 
 
 
 
4. BATCH NUMBER 
 
LOT: 
 
 
5. OTHER 
 
 
 
  



49 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET 
 
 

  



50 

Package leaflet: Information for the patient 
 

Galafold 123 mg hard capsules 
Migalastat 

 
This medicine is subject to additional monitoring. This will allow quick identification of new 

safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects. 
 
Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor, pharmacist, or nurse. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible 

side effects not listed in this leaflet. See section 4. 
 
What is in this leaflet 
 
1. What Galafold is and what it is used for 
2. What you need to know before you take Galafold 
3. How to take Galafold 
4. Possible side effects 
5. How to store Galafold 
6. Contents of the pack and other information 
 
 
1. What Galafold is and what it is used for  
 
Galafold contains the active substance migalastat. 
 
This medicine is used for the long-term treatment of Fabry disease in adults and adolescents aged 
16 years and older who have certain genetic mutations (changes).  
 
Fabry disease is caused by the lack of or a faulty enzyme called alpha-galactosidase A (α-Gal A). 
Depending upon the kind of mutation (change) in the gene that produces α-Gal A, the enzyme does 
not work properly or is completely absent. This enzyme defect leads to abnormal deposits of a fatty 
substance known as globotriaosylceramide (GL-3) in kidneys, heart, and other organs, leading to the 
symptoms of Fabry disease.  
 
This medicine works by stabilising the enzyme that your body produces naturally, so that it can work 
better to reduce the amount of GL-3 that has accumulated in your cells and tissues. 
 
 
2. What you need to know before you take Galafold 
 
Do not take Galafold if you: 

• are allergic to migalastat or any of the other ingredients of this medicine (listed in section 6). 
 
Warnings and precautions  
Talk to your doctor before taking Galafold if you are currently taking enzyme replacement therapy. 
You should not take Galafold if you are also receiving enzyme replacement therapy.  
 
Your doctor will monitor your condition and whether your medicine is working every 6 months while 
you are taking Galafold. If your condition worsens, your doctor may evaluate you further or may 
discontinue your treatment with Galafold. 



51 

 
Children and adolescents 
This medicine has not been studied in children and adolescents under the age of 16 years; therefore, 
the safety and efficacy in this age group has not been established. 
 
Other medicines and Galafold 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other 
medicines because certain other medicines may increase or decrease the amount of Galafold in your 
body.  
 
Pregnancy, breast-feeding, and fertility 
 
Pregnancy 
There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, 
think you may be pregnant, or are planning to have a baby, do not take this medicine until you have 
checked with your doctor, pharmacist, or nurse. While taking Galafold you should use effective birth 
control.  
 
Breast-feeding 
Do not take this medicine if you are breast-feeding, until you have spoken with your doctor, 
pharmacist, or nurse. It is not yet known whether this medicine passes into breast milk. Your doctor 
will decide whether you need to stop breast-feeding or temporarily stop your medicine. 
 
Fertility in men 
It is not yet known if this medicine affects fertility in men. The effects of Galafold on fertility in 
humans have not been studied. 
 
Fertility in women 
It is not yet known if this medicine affects fertility in women. 
 
If you are planning to have a baby, ask your doctor, pharmacist, or nurse for advice. 
 
Driving and using machines 
 
It is unlikely that this medicine will affect your ability to drive and use machines. 
 
 
3. How to take Galafold 
 
Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your 
doctor, pharmacist, or nurse if you are not sure. 
 
Take one capsule every other day at the same time of the day. Do not take Galafold on two 
consecutive days. 
 
Do not eat food at least 2 hours before and 2 hours after taking your medicine. This minimum 4 hours 
fast around taking your medicine is needed to allow your medicine to be fully absorbed. Clear liquids, 
including carbonated drinks, can be consumed during this period. 
 
Swallow the capsule whole. Do not cut, crush, or chew the capsule. 
  



52 

 

Figure A 

 

Step 1: Remove the adhesive seal holding the 
cover. 
Lift the cover of your Galafold carton 
(See Figure A). 

Figure B – Opened carton 

 

Step 2: Press and continue holding down the 
purple tab with your thumb at the left 
side of the carton (See Figure B), and 
continue to Step 3. 

Figure C 

 

Step 3: Now GRASP the tab on the right side 
where it says “PULL OUT HERE” and  
pull out the folded blister card  
(See Figure C). 

Figure D – Front of the blister card  

 

Step 4: Unfold the blister card 
(See Figure D). 



53 

Taking Galafold Capsule: 
One Galafold blister card = 14 hard capsules = 28 days of treatment with Galafold, and  

14 white cardboard circles. 
The white cardboard circles are to remind you to take Galafold every other day. 
The arrow directs the patient to begin the next 2 weeks of treatment. 
 
Figure E – Front of the blister card 

 
 

Figure F – Front of the blister card 
 
 
 
 
 
 
 
 
 
 
 
 

 

Step 5: On your first day of taking this 
medicine from a new blister card, 
record the date on the blister card 
(See Figure F).  

Figure G – Back of the blister card  

 
 
 
 
 
 
 
 
 
 
 

 
 

Step 6: TURN the card OVER showing  
the back of the card. 

LOCATE capsule to remove.  
BEND the card as shown (Figure G). 
 

Note: Bending the card helps raise the oval 
perforated cardboard. 



54 

Figure H – Back of the blister card 

 

Step 7: REMOVE the oval perforated

cardboard (See Figure H). 
 

Note: After removing the cardboard,  
the white backing of the foil may be 
present, which is ok. 

Figure I – Front of the blister card 

 

Step 8: TURN the card OVER showing the  
front of the card. 
 
PUSH the capsule out 
(See Figure I). 

Figure J – Front of the blister card 

 

Step 9: On the next day, move to the perforated 
white cardboard circle on the top row 
labelled Day 2.  
Press down on the white cardboard 
circle removing it (see Figure J). 
 

Note: Removing this white circle will help  
you remember which day you do not 
take the medicine. 
 
Take 1 Galafold capsule every other 
day. 
 
Close package and store after each use. 



55 

After Day 2, move to Day 3 on the blister card.  
Alternate daily between taking the capsule and pushing out the perforated white cardboard circles, 
up to and including day 28. 

Figure K – Front of the unfolded blister card 

 
 
If you take more Galafold than you should 
If you take more capsules than you should, then you should stop taking the medicine and contact your 
doctor. You may get a headache and feel dizzy. 
 
If you forget to take Galafold 
If you forget to take your capsule at the usual time but remember later, you can take the capsule only if 
it is within 12 hours of your normal dosing time. If more than 12 hours has passed you should resume 
taking Galafold at the next planned dosing day and time according to your every other day dosing 
schedule. Do not take two capsules to make up for your missed dose. 
 
If you stop taking Galafold 
Do not stop taking this medicine without talking to your doctor. 
 
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse. 
 
 
4. Possible side effects 
 
Like all medicines, this medicine can cause side effects, although not everybody gets them. 
 
 
Very common: may affect more than 1 in 10 people 
• Headache 
 
Common: may affect up to 1 in 10 people 
 



56 

• Palpitations (the feeling 
of a pounding heart) 

• Sensation of spinning 
(vertigo) 

• Diarrhoea  
• Feeling sick (nausea) 
• Stomach ache 
• Constipation  
• Dry mouth 
• Sudden need to defecate 
• Indigestion (dyspepsia) 
• Tiredness 
• raised levels of creatine 

phosphokinase in blood 
tests  

• Weight gain 
• Muscle spasms 
• Muscle pain (myalgia) 
• Painful stiff neck 

(torticollis) 
• Tingling in extremities 

(paraesthesia) 
• Dizziness  
• Reduced sense of touch 

or sensation 
(hypoaesthesia) 

• Depression  
• Protein in the urine 

(proteinuria)  

• Shortness of breath 
(dyspnoea) 

• Nose bleed (epistaxis) 
• Rash  
• Persistent itch (pruritus) 
• Pain

 
Reporting of side effects 
 
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. 
 
 
5. How to store Galafold 
 
Keep this medicine out of the sight and reach of children. 
 
Do not use this medicine after the expiry date, which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. 
 
This medicinal product does not require any special temperature storage conditions. Store in the 
original package in order to protect from moisture. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. 
 
 
6. Contents of the pack and other information  
 
What Galafold contains  
- The active substance is migalastat. Each capsule contains migalastat hydrochloride equivalent to 

123 mg migalastat 
- The other ingredients are: 

Capsule contents: Pregelatinised maize starch and magnesium stearate 
Capsule shell: Gelatin, titanium dioxide (E171), and indigotine (E132) 
Printing ink: Shellac, black iron oxide, and potassium hydroxide 

 
What Galafold looks like and contents of the pack 
Opaque, blue, and white hard capsules, marked with “A1001” in black ink, containing white to pale 
brown powder. 
 
Galafold is available in a blister pack containing 14 capsules. 
 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

57 
 

Marketing Authorisation Holder 
Amicus Therapeutics Europe Limited 
Block 1, Blanchardstown Corporate Park 
Ballycoolin Road 
Blanchardstown, Dublin  
D15 AKK1 
Ireland 
Tel: +353 (0) 1 588 0836 
Fax: +353 (0) 1 588 6851 
e-mail: info@amicusrx.co.uk 
 
Manufacturer 
Almac Pharma Services (Ireland) Limited 
Finnabair Industrial Estate 
Dundalk, Co. Louth 
A91 P9KD 
Ireland 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder (if you cannot reach your Amicus representative by phone please contact via the 
e-mail address listed below): 
 
België/Belgique/Belgien 
Amicus Therapeutics Europe Limited 
Tél/Tel: 0800 89172 
e-mail: MedInfo@amicusrx.com 
 

Lietuva 
Amicus Therapeutics Europe Limited  
Tel.: 8800 33167 
El. paštas: MedInfo@amicusrx.com 

България 
Amicus Therapeutics Europe Limited  
Teл.: 00800 111 3214 
имейл: MedInfo@amicusrx.com 
 

Luxembourg/Luxemburg 
Amicus Therapeutics Europe Limited  
Tél/Tel: 800 27003 
e-mail: MedInfo@amicusrx.com 

Česká republika 
Amicus Therapeutics Europe Limited  
Tel.: 800 142 207 
e-mail: MedInfo@amicusrx.com 
 

Magyarország 
Amicus Therapeutics Europe Limited  
Tel.: 06 800 21202 
e-mail: MedInfo@amicusrx.com 

Danmark 
Amicus Therapeutics Europe Limited  
Tlf.: 80 253 262 
e-mail: MedInfo@amicusrx.com 
 

Malta 
Amicus Therapeutics Europe Limited  
Tel: 800 62674 
e-mail: MedInfo@amicusrx.com 
 

Deutschland 
Amicus Therapeutics GmbH 
Tel.: + 49 89 2488 79810 / 0800 000 2038 
E-Mail: MedInfo@amicusrx.com 
 

Nederland 
Amicus Therapeutics BV 
Tel: + 31 20 235 8510 / 0800 022 8399 
e-mail: MedInfo@amicusrx.com 

Eesti 
Amicus Therapeutics Europe Limited  
Tel: 800 0111 911 
e-post: MedInfo@amicusrx.com 
 

Norge 
Amicus Therapeutics Europe Limited  
Tlf: 800 13837 
e-post: MedInfo@amicusrx.com 



 

58 
 

Ελλάδα 
Amicus Therapeutics Europe Limited  
Τηλ.: 00800 126 169 
e-mail: MedInfo@amicusrx.com 
 

Österreich 
Amicus Therapeutics Europe Limited  
Tel: 0800 005 475 
E-Mail: MedInfo@amicusrx.com 

España 
Amicus Therapeutics S.L.U. 
Tel: 900 941 616  
e-mail: MedInfo@amicusrx.com 
 

Polska 
Amicus Therapeutics Europe Limited  
Tel.: 0080 012 15475 
e-mail: MedInfo@amicusrx.com 

France 
Amicus Therapeutics SAS 
Tél: 0800 906 788 
e-mail: MedInfo@amicusrx.com 
 

Portugal 
Amicus Therapeutics Europe Limited  
Tel: 800 812 531 
e-mail: MedInfo@amicusrx.com 

Hrvatska 
Amicus Therapeutics Europe Limited  
Tel: 0800 222 452 
e-pošta: MedInfo@amicusrx.com 
 
Ireland 
Amicus Therapeutics Europe Limited  
Tel: 1800 936 230 
e-mail: MedInfo@amicusrx.com 
 

România 
Amicus Therapeutics Europe Limited  
Tel.: 0808 034 288 / 877 309 5040 
e-mail: MedInfo@amicusrx.com 
 
Slovenija 
Amicus Therapeutics Europe Limited  
Tel.: 0800 81794 
e-pošta: MedInfo@amicusrx.com 
 

Ísland 
Amicus Therapeutics Europe Limited  
Sími: 800 7634 
Netfang: MedInfo@amicusrx.com 

Slovenská republika 
Amicus Therapeutics Europe Limited  
Tel.: 0800 002 437 
e-mail: MedInfo@amicusrx.com 

 
Italia 
Amicus Therapeutics S.r.l. 
Tel: 800 795 572 
e-mail: MedInfo@amicusrx.com 

 
Suomi/Finland 
Amicus Therapeutics Europe Limited  
Puh/Tel: 0800 917 780 
sähköposti/e-mail: MedInfo@amicusrx.com 
 

Κύπρος 
Amicus Therapeutics Europe Limited  
Τηλ.: 800 97595 
e-mail: MedInfo@amicusrx.com 
 

Sverige 
Amicus Therapeutics Europe Limited  
Tfn: 020 795 493 
e-post: MedInfo@amicusrx.com 
 

Latvija 
Amicus Therapeutics Europe Limited  
Tel.: 800 05391 
e-pasts: MedInfo@amicusrx.com 
 

United Kingdom 
Amicus Therapeutics, UK Limited  
Tel: +44 175 3888 567 / 08 0823 46864  
e-mail: MedInfo@amicusrx.com 

 
This leaflet was last revised in  
 
Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. 

http://www.ema.europa.eu/

	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET